Walleye Capital LLC Aurinia Pharmaceuticals Inc. Transaction History

Walleye Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.93 - $9.31 $6,305 - $11,907	1,279 New	1,279 $6,000
Q4 2022 Feb 14, 2023	SELL	$4.11 - $8.14 $881,442 - $1.75 Million	-214,463 Reduced 72.28%	82,245 $355,000
Q3 2022 Nov 14, 2022	BUY	$6.66 - $12.39 $1.98 Million - $3.68 Million	296,708 New	296,708 $2.23 Million
Q2 2022 Aug 08, 2022	SELL	$8.95 - $12.8 $309,544 - $442,700	-34,586 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$10.05 - $22.48 $347,589 - $777,493	34,586 New	34,586 $428,000
Q1 2020 May 15, 2020	SELL	$11.34 - $21.46 $777,583 - $1.47 Million	-68,570 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.88 - $21.42 $266,051 - $1.47 Million	68,570 New	68,570 $1.39 Million

191

56.2M

499K

637K

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.03B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.